About this trial
this study aims to assess the gluteus maximus muscle electromyographic activity and the latissimus dorsi muscle electromyographic activity in patients with shoulder impingement syndrome , to improve the assessment procedure and the rehabilitation program for treating patients with shoulder impingement syndrome more effectively. .
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Both male and female patients with shoulder impingement syndrome.
patients complain from unilateral shoulder pain with chronic conditions of SIS ≥ 3 months.
Patient age from 25 to 40 years.
Patients with Positive impingement tests.
Disqualifiers
Patients with Numbness or tingling of upper extremity.
Patients with Shoulder fracture or previous shoulder surgery, and Acromioclavicular or shoulder dislocation.
Patients with Any traumatic injury to the lower limb in the previous 6 months.
Any spine surgery within the last 2 years.
Trial population
All patients will be referred by an orthopedic surgeon who will diagnose SIS based on clinical and radiological examination.
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
electromyography
Deviceelectromyographic activity of posterior oblique sling muscles will be measured
Treatment groups
Trial outcomes
Primary outcomes
• electromyographic activity of posterior oblique sling muscles (gluteus maximus and latissimus dorsi)
EMG has been widely used for many decades, its use is proven and widely accepted by clinicians and the scientific community and it is considered the gold standard method for the measurement of muscle activity.
Secondary outcomes
shoulder active range of motion
Universal goniometry is frequently used by physical therapists to assess ROM due to its ease of use, portability, noninvasive nature, and low cost.
shoulder function and disability level
The Arabic Q-DASH questionnaire has demonstrated good reliability, validity, and responsiveness when used for patients with upper extremity disorders.
shoulder pain
The ordinal 11-point NPRS (0-no pain, 10-most intense pain) has good test-retest reliability (r=.79-.96) in individuals with chronic pain and musculoskeletal pathology.
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: